A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical applications with no systematic review or meta-analysis methodology
PubMed 33249990 · doi:10.1177/1078155220975825
What was done
The authors conducted a narrative review of literature sourced from Google Scholar and PubMed (MEDLINE) on thalidomide. The review summarizes its mechanisms of action (anti-angiogenic, anti-inflammatory, and cytokine-modulating effects via tumor necrosis factor-α, cereblon, and tubulin), teratogenic risk prevention strategies (System for Thalidomide Education and Prescribing Safety), and clinical trial findings across various malignancies and inflammatory diseases.
What was found
No quantitative trial results, effect sizes, or participant numbers are reported in the abstract. The text provides historical context (~10,000 children affected in the 1960s; teratogenic window of 20–34 days post-fertilization) and notes FDA approvals for erythema nodosum leprosum and multiple myeloma, alongside clinical activity in advanced renal, esophageal, refractory endometrial, and pancreatic cancers, as well as autoimmune and inflammatory bowel disorders.
Why it matters
The paper outlines how mechanistic understanding and strict risk-mitigation programs enabled the therapeutic repositioning of a historically notorious teratogen into an approved oncologic and immunologic therapy.
Limits
This is a non-systematic narrative review without formal quality assessment, risk-of-bias grading, or quantitative meta-analysis. The abstract provides no specific numerical endpoints, patient counts, or comparative safety and efficacy data.
Cited by
- supports Thalidomide was originally developed as an anti-nausea drug for pregnant women, was removed from the market due to causing severe limb-reduction birth defects, and was later FDA-approved for leprosy and multiple myeloma due to its anti-angiogenic properties.